Contents

List of Contributors *xxi*
Foreword by Dr. Steven M. Fox *xxiii*
Foreword by Laura Eldridge *xxv*
Acknowledgments *xxvi*
About the Companion Website *xxvii*

Part 1 Laying the Groundwork: Principles and Framework for Modern OA Care *1*

1 Read with Purpose: How to Approach This Book *3*
Kristin Kirkby Shaw and Hannah Capon
1.1 Introduction: Why This Book *3*
1.2 What to Expect from This Book *3*
1.3 Guiding Principles of the OA Blueprint and This Textbook *4*
1.4 What Comes Next *5*
1.5 Final Thoughts *5*

2 The OA Blueprint *6*
Kristin Kirkby Shaw and Hannah Capon
2.1 The OA Blueprint *6*
2.2 Awareness *6*
2.3 Screening *7*
2.4 Diagnosis *7*
2.5 Plan *7*
2.6 Recheck *9*
2.7 Lifelong Management *9*
2.8 Summary *9*

3 What We Are Up Against: Understanding OA and Maladaptive Pain *10*
Kristin Kirkby Shaw and Duncan Lascelles
3.1 The Joint Is an Organ *10*
3.2 What Exactly *Is* Osteoarthritis? *10*
3.3 The Disease of OA *11*
3.3.1 Molecular Mechanisms of OA *11*
Cartilage Degeneration *12*
The Synovium and Inflammatory Cytokines *12*
Neurogenic Inflammation *13*
3.3.2 Macroscopic Changes to the Joint with OA *13*
3.3.3 Pathology vs. Radiology *16*
3.4 Why Do Dogs Develop OA? *16*
3.4.1 Role of Systemic Inflammation *18*

COPYRIGHTED MATERIAL

3.5 Clinical OA: The Disease of Maladaptive Pain *18*
3.5.1 Defining Types of Pain *18*
3.5.2 Nociceptive Pain *19*
3.5.3 Inflammatory Pain *20*
3.5.4 Maladaptive Pain *20*
3.5.5 Neuropathic Pain *21*
3.5.6 Nociplastic Pain *21*
3.6 Generation of Nociceptive Signals in OA *21*
3.6.1 The Pain Pathway *21*
3.6.2 Joint Innervation *22*
3.6.3 Molecular Mediators of OA Pain *23*
3.7 Beyond the Biology: The Biopsychosocial Model of Pain *23*
3.8 Conclusion *24*
References *24*

Part 2 Set the Stage for Success: People, Patients, and Practice Culture *29*

4 The Role of Fear and Anxiety in OA Care *31*
Margaret Gruen and Michael Khan
4.1 Pain as a Teacher *31*
4.1.1 Neurobiology *31*
4.2 Behavioral Changes in Dogs as a Result of Chronic OA Pain *31*
4.2.1 New and Worsening Fears *32*
4.2.2 Aggression *33*
4.2.3 Changes to Routine *34*
4.3 Behavioral Considerations with Veterinary Care *34*
References *35*

5 *"But My Dog Isn't Crying Out."* How to Talk with Caregivers About OA and Pain *37*
Hannah Capon
5.1 Before You Skip This Chapter … *37*
5.1.1 What Are Great Outcomes? *37*
5.2 Effective Communication in Veterinary Practice *38*
5.2.1 Personalized Communication: A Two-Way Exchange *38*
5.2.2 Client-Centered Care: The Foundation of Effective Communication *39*
5.2.3 The Role of Empathy in Communication *40*
5.3 The Biopsychosocial Approach in Veterinary Care *40*
5.4 Setting Yourself Up for Success: Sustaining the Best Version of Yourself *41*
5.5 Managing Canine OA Is a Journey of Many Legs *41*
5.5.1 Screening and Identification *42*
5.5.2 Diagnosis *43*
5.5.3 Initial Treatment Plan *44*
5.5.4 Revised Treatment Plan *46*
5.5.5 End of Life Care *46*
5.6 Maintaining Caregiver Engagement *47*
References *48*

6 It Takes a Village: A Team-Based Approach to Osteoarthritis Management *49*
Jerrod Johnson
6.1 Introduction *49*
6.2 The Team *50*
6.2.1 Client Service Representative/Reception Team/Administration Team *50*
6.2.2 Veterinary Technician/Nurse *51*
6.2.3 Veterinary Assistant *51*
6.2.4 Veterinarian *52*
6.2.5 Specialist/Referral Team *52*
6.2.6 Allied Canine Professionals *52*
6.2.7 Caregiver and Patient *53*
6.3 Why a Team Approach Matters *53*
References *54*

7 Tech to Tech: How to Be the Best OA Advocate for Your Patients *55*
Stephen Niño Cital
7.1 Introduction *55*
7.2 Veterinary Technician Autonomy *55*
7.3 Technicians in the Recognition and Advocacy for Physical and Psychological Pain Management *56*
7.4 Preparing for the Visit: A Pre-, During-, and Post-Visit Affair *56*
7.4.1 Low Stress: Not Just for Psychological Safety, But Patient Comfort *56*
7.4.2 Making the Lobby and Exam Room Pain- and Stress-Free *57*
7.4.3 The Pre-Visit *57*
7.4.4 Post-Visit *57*
7.5 The In-hospital Experience *58*
7.5.1 Cage/Kennel Setup for Animals in Pain *58*
7.5.2 Preparing Procedure and Surgical Tables for Patients to Reduce Pain *58*
7.6 Technician-Led Education and Communication *59*
7.6.1 Taking Pain (Acute/Chronic)-Focused Histories *59*
7.6.2 Educating Clients on Metrology Tools *59*
7.6.3 Education on Nutrition *59*
7.6.4 Coaching Clients on Lifestyle Adaptations for Animals with Pain *60*
7.7 Team Approach to Diagnosis (Tech Focus) *60*
7.7.1 Assisting in a Physical Examination *60*
7.8 Veterinary Technician-Led Chronic Treatment Appointments *60*
7.8.1 Veterinary Technicians Supporting Long-term Treatment Strategies *60*
7.8.2 Assisting or Performing Treatments *61*
7.9 Conclusion *61*
Reference *62*

8 How to Create an OA-Friendly Clinic and Consult *63*
Tamsin Durston
8.1 Introduction *63*
8.2 What It Means to Be a Dog with OA *63*
8.3 What This Means for a Dog with OA Visiting the Veterinary Clinic *64*
8.4 Promoting Physical and Psychological Safety Within the Clinic *65*
8.5 Client Education *68*
References *70*

Part 3 From Suspicion to Confirmation: The Art and Science of Diagnosing OA *73*

9 When It's Not So Simple: Differential Diagnoses for OA Lameness and Common Comorbidities That May Impact Your Plan *75*
Wanda Gordon-Evans
9.1 Introduction *75*
9.2 Differential Diagnoses for OA *76*
9.2.1 Immune-Mediated Polyarthritis *76*
9.2.2 Septic Arthritis *78*
9.2.3 Soft-Tissue Musculoskeletal Injury *79*
9.2.4 Periarticular Neoplasia *79*
9.2.5 Conditions Affecting the Paws *80*
9.3 Comorbidities *80*
9.3.1 Obesity *81*
9.3.2 Systemic Disease *81*
9.3.3 Sarcopenia *82*
9.3.4 Neurologic Conditions *82*
9.3.5 Geriatric Onset Laryngeal Paralysis and Polyneuropathy (GOLPP) *82*
9.3.6 Lumbosacral (LS) Disease *82*
References *83*

10 It Starts with an Index of Suspicion: Screening Tools for Identifying OA *85*
Kristin Kirkby Shaw
10.1 Why Screen for OA *85*
10.2 Predisposing Factors for OA *85*
10.3 When Do Dogs Start Developing Evidence of OA? *86*
10.4 What Are the Earliest Signs of OA Pain? *86*
10.5 WHEN and WHO to Screen for OA *86*
10.6 Engage Caregivers to Help Identify Signs of OA *88*
10.7 The 60-Second OA Screening Exam *89*
References *91*

11 The Art of the Musculoskeletal Exam: Using Low-Stress Techniques to Establish a Diagnosis of Joint Disease *93*
Kristin Kirkby Shaw and Ross Palmer
11.1 Obtaining a Comprehensive MSK History *93*
11.1.1 Clues in the History *93*
11.1.2 The MSK History Questionnaire *93*
11.2 Why Perform a Low-Stress Musculoskeletal Exam *97*
11.2.1 How to Set up for a Successful MSK Exam Experience *97*
11.3 How to Perform the Low-Stress MSK Exam *98*
11.3.1 Observation *98*
11.3.2 Palpation *104*
That "WAS CREAPI" *105*
Standing Exam *106*
Neurologic Screening Exam *107*
11.4 Individual Limb Assessment *107*
11.4.1 Thoracic Limb *108*
Shoulder *108*
Axilla *109*
Elbow *109*
Antebrachium *109*

Carpus *110*
Metacarpals and Digits *110*
11.4.2 Pelvic Limb *110*
Hip *110*
Stifle *110*
Tarsus *113*
Metatarsals and Digits *113*
11.5 Juvenile Dog Hip Exam *113*
References *116*

12 Diagnostic Imaging Techniques and Radiographic Features of OA *117*
Matthew D. Winter and Danielle Mauragis
12.1 Introduction to Diagnostic Imaging *117*
12.2 Diagnostic Imaging Modalities: Strengths and Limitations *117*
12.2.1 Radiography *117*
12.2.2 Ultrasound *118*
12.2.3 Computed Tomography (CT) *118*
12.2.4 Magnetic Resonance Imaging (MRI) *118*
12.3 Principles of Radiographic Interpretation *119*
12.3.1 Systematic Approach to Interpretation *119*
12.4 Organizing Your Approach *120*
12.4.1 Description of Abnormal Findings *121*
12.4.2 Synthesis *121*
12.4.3 Next Steps *121*
12.5 Radiographic Features of Osteoarthritis *121*
12.5.1 Synovial Volume and Periarticular Swelling *122*
12.5.2 Osteophytes *123*
12.5.3 Enthesophytes *123*
12.5.4 Joint Space Narrowing *125*
12.5.5 Changes in Subchondral Bone Opacity *125*
12.5.6 Subluxation *126*
12.6 Positioning for Success *127*
12.7 Joint-specific Imaging *128*
12.7.1 Shoulder *128*
Lateral Projection *129*
Caudal-to-Cranial *129*
Pronated Lateral *130*
Supinated Lateral *130*
Bicipital Groove View (Specialized) *130*
12.7.2 Elbow *131*
Lateral Positioning (Neutral) *131*
Flexed Lateral *132*
Cranial-to-Caudal *132*
Cranio-15° Medial Caudolateral Oblique *133*
12.7.3 Carpus/Metacarpus *135*
12.7.4 Lateral Positioning *135*
General Positioning *135*
Neutral Lateral *135*
Flexed Lateral *135*
Extended Lateral *136*
Dorsopalmar Projection *136*
Pronated Dorsopalmar (35° Inward Toward Midline) *137*

Supinated Dorsopalmar (35° Outward from Midline) *137*
12.7.5 Pelvis/Hips *139*
Lateral View *139*
Ventrodorsal View *139*
Frog-Leg View *140*
12.7.6 Stifle *142*
Neutral Lateral *142*
Caudal-to-Cranial (Preferred) *142*
Cranial-to-Caudal (Alternative) *143*
12.7.7 Tarsus *146*
Lateral Positioning *146*
Neutral Lateral *146*
Flexed Lateral *146*
Extended Lateral *147*
Dorsoplantar Projections *147*
Pronated Dorsoplantar (DLPMO) (35° Inward Toward Midline) *147*
Supinated Dorsoplantar (DMPLO) (35° Outward from Midline) *148*
12.7.8 Phalanges *150*
Digit Separation for Mediolateral Views *150*
Dorsoplantar Projection (Pelvic Limb) *150*
Dorsopalmar Projection (Thoracic Limb) *151*
12.8 Summary *153*
References *153*

13 Put a Number on It: Stages, Grades, and Use of Clinical Metrology Instruments for OA *155*
Mark E. Epstein, Kristin Kirkby Shaw, and Hannah Capon
13.1 Introduction *155*
13.2 CMIs for Canine Chronic Pain *156*
13.2.1 Canine Brief Pain Inventory (CBPI) *157*
13.2.2 Canine Orthopedic Index (COI) *158*
13.2.3 Liverpool Osteoarthritis in Dogs (LOAD) *159*
13.2.4 Client-Specific Outcome Measures (CSOM) *161*
13.3 Incorporating a CMI into General Practice *163*
13.4 Canine Osteoarthritis Staging Tool (COAST) *163*
13.4.1 Why Use COAST *164*
13.5 Incorporating COAST Into General Practice *165*
References *166*

14 How to Develop and Modify Your Plan *169*
Hannah Capon
14.1 Introduction *169*
14.2 The Bigger Picture of OA Management *170*
14.2.1 Frameworks to Guide Development and Modification of Multimodal Care Plans *170*
14.2.2 The Blueprint *171*
14.2.3 The Canine Osteoarthritis Staging Tool *172*
14.2.4 The OA *Disease* and *Illness* Model *172*
14.2.5 Return to Function Framework *173*
14.3 Considering the Evidence *174*
14.4 Carving the Initial Plan *175*
14.4.1 Clinical Priorities *177*
14.4.2 Communication and Contextualized Care *177*
14.4.3 Logistics *178*

14.5 OA, Acute-on-Chronic Pain – Identifying and Preparing Clients for Flares *179*
14.6 Your Role in the Care Plan *179*
14.7 Modifying the Care Plan *179*
14.7.1 Comfortable and Well-maintained on the Current Treatment Plan *180*
14.7.2 Identification of an Insufficient Plan at a Scheduled Reassessment *180*
14.7.3 Unexpected Deterioration *181*
References *182*

Part 4 Building Your Plan: The Essentials of OA Management *185*

15 Pharmaceutical Options for OA Management *187*
Melina Zimmerman and Kristin Kirkby Shaw
15.1 Introduction to Pharmaceutical Management of Canine Osteoarthritis *187*
15.1.1 Types of Pain Experienced with OA *187*
15.2 Nonsteroidal Anti-inflammatory Medications (NSAIDs) *188*
15.2.1 Mechanism of Action *188*
15.2.2 PGE_2 as a Therapeutic Target *189*
15.2.3 Evidence for Use for OA/Chronic Pain in Dogs *191*
15.2.4 Clinical Indications *191*
15.2.5 Dosing Recommendations *191*
15.2.6 Contraindications and Precautions *192*
15.2.7 Potential Side Effects *192*
15.2.8 Other Considerations *193*
15.3 Anti-Nerve Growth Factor Monoclonal Antibodies (Anti-NGF mAbs) *193*
15.3.1 Mechanism of Action *193*
15.3.2 Anti-NGF mAbs *195*
15.3.3 Evidence for Use for OA/Chronic Pain in Dogs *195*
15.3.4 Clinical Indications *195*
15.3.5 Dosing Recommendations for Bedinvetmab *195*
15.3.6 Contraindications and Precautions *196*
15.3.7 Potential Side Effects Reported for Bedinvetmab *196*
15.3.8 Other Considerations *197*
15.4 Acetaminophen *198*
15.4.1 Mechanism of Action *198*
15.4.2 Evidence for Use in OA/Chronic Pain in Dogs *198*
15.4.3 Clinical Indications *198*
15.4.4 Dosing Recommendations *198*
15.4.5 Contraindications and Precautions *198*
15.4.6 Potential Side Effects *198*
15.4.7 Other Considerations *198*
15.5 NMDA Antagonists *199*
15.5.1 Mechanism of Action *199*
15.5.2 Evidence for Use in OA/Chronic Pain in Dogs *199*
15.5.3 Clinical Indications *199*
15.5.4 Dosing Recommendations *199*
Ketamine *199*
Amantadine *199*
Memantine *200*
15.5.5 Potential Side Effects *200*
15.5.6 Other Considerations *200*
15.6 Gabapentinoids *200*

15.6.1 Mechanism of Action *200*
15.6.2 Evidence for use in OA/Chronic Pain in Dogs *200*
15.6.3 Clinical Indications *201*
15.6.4 Dosing Recommendations *201*
15.6.5 Contraindications and Precautions *201*
15.6.6 Potential Side Effects *201*
15.6.7 Other Considerations *201*
15.7 Anxiolytics *202*
15.7.1 Tricyclic Antidepressants (TCAs) *202*
Mechanism of Action *202*
Evidence for Use in OA/Chronic Pain in Dogs *202*
Clinical Indications *202*
Dosing Recommendations *202*
Contraindications and Precautions *202*
Potential Side Effects *203*
Other Considerations *203*
15.7.2 Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) *203*
Mechanism of Action *203*
Evidence for use in OA/Chronic Pain in Dogs *203*
Clinical Indications *203*
Dosing Recommendations *203*
Contraindications and Precautions *203*
Potential Side Effects *203*
Other Considerations *204*
15.7.3 Selective Serotonin Reuptake Inhibitors (SSRIs) *204*
Mechanism of Action *204*
Evidence for use in OA/Chronic Pain in Dogs *204*
Clinical Indications *204*
Dosing Recommendations *204*
Contraindications and Precautions *204*
Potential Side Effects *204*
Other Considerations *205*
15.7.4 Alpha-2 Adrenergic Agonists *205*
Mechanism of Action *205*
Evidence for use in OA/Chronic Pain in Dogs *205*
Clinical Indications *205*
Dosing Recommendations *205*
Contraindications and Precautions *205*
Potential Side Effects *205*
Other Considerations *205*
15.8 Muscle Relaxants *206*
Mechanism of Action *206*
Evidence for use in OA/Chronic Pain in Dogs *206*
Clinical Indications *206*
Dosing Recommendations *206*
Contraindications and Precautions *206*
Potential Side Effects *207*
Other Considerations *207*
15.9 Opioids *207*
15.9.1 Injectable Full Mu Opioid Agonists *207*
Mechanism of Action *207*
Evidence for use in OA/Chronic Pain in Dogs *207*

Clinical Indications *207*
Dosing Recommendations *207*
Contraindications and Precautions *207*
Potential Side Effects *207*
Other Considerations *207*
15.9.2 Oral Opioids *208*
Mechanism of Action *208*
Evidence for use in OA/Chronic Pain in Dogs *208*
Clinical Indications *208*
Dosing Recommendations *208*
Contraindications and Precautions *208*
Potential Side Effects *208*
Other Considerations *208*
15.9.3 Oral Transmucosal Opioids *209*
Mechanism of Action *209*
Evidence for use in OA/Chronic Pain in Dogs *209*
Clinical Indications *209*
Dosing Recommendations *209*
Contraindications and Precautions *209*
Potential Side Effects *209*
Other Considerations *209*
References *213*

16 The Biggest Impact: Weight Management and Nutrition for Canine OA *219*
Joe Wakshlag, Ernie Ward, and Kristin Kirkby Shaw
16.1 Introduction: Why This Chapter Is So Important *219*
16.2 Defining Excess Adiposity *220*
16.2.1 Overweight vs. Obesity *220*
16.2.2 Diagnosing Excess Adiposity *221*
16.3 Health Implications of Canine Obesity *221*
16.3.1 Prevalence *221*
16.3.2 Contributors, Comorbidities, and Consequences *222*
16.3.3 Obesity and OA *223*
16.3.4 Excess Adiposity and Quality of Life *224*
16.4 Discussing Excess Adiposity with Caregivers *224*
16.4.1 Tips for Talking to Caregivers About Weight Management *224*
16.5 How to Develop a Weight Loss Plan *227*
16.6 Nutritional Recommendations for Puppies/Growing Dogs *236*
16.6.1 Protein Recommendations for Growing Dogs *237*
16.6.2 The Importance of Calcium and Phosphorus Balance *237*
16.6.3 Gonadectomy and Obesity (and OA) *237*
16.6.4 Best Practices for Feeding Growing Puppies *238*
16.7 Feeding Geriatric Dogs with OA for Weight Loss *238*
16.7.1 Protein Requirements in Aging Dogs *238*
16.8 Omega-3 Fatty Acids and Weight Loss *239*
16.8.1 Omega-3 Fatty Acid Supplementation Recommendations *239*
16.8.2 Dosing Considerations *239*
16.9 Barriers to Weight Loss *240*
16.9.1 3 Steps to Achieving Client Compliance for Weight Loss *240*
References *242*

17 Use It or Lose It: The Crucial Role of Exercise in OA Management *247*
Kara Amstutz
17.1 Introduction *247*
17.2 The Role of Exercise in the Osteoarthritic Patient *247*
17.2.1 Exercise Attenuates Pain *247*
17.2.2 Caution! The Wrong Type of Exercise Can Induce Pain *248*
17.2.3 Exercise Assists with Weight Loss *249*
17.2.4 Exercise Modulates Osteoarthritis Progression *249*
17.2.5 Exercise Maintains Muscle Mass *250*
17.2.6 Exercise Boosts Mobility *250*
17.2.7 Exercise Maintains Proprioception *250*
17.2.8 Exercise Slows Cognitive Decline *251*
17.3 Exercise Prescription for the OA Patient *251*
17.3.1 Strength Exercises *252*
17.3.2 Proprioception and Balance Exercises *253*
17.3.3 Joint Range of Motion and Muscle Flexibility Exercises *253*
17.3.4 Endurance Exercises *255*
17.3.5 Walking *255*
References *257*

18 OA Is a Way of Life: Home and Environmental Modifications *260*
Hannah Capon
18.1 Introduction *260*
18.2 The Consequences of Persistent OA Pain *261*
18.2.1 Functional Mobility Is Reduced with OA Pain *261*
18.2.2 Psychological Safety Is Threatened by OA Pain *262*
18.2.3 Comorbidities and Frailty Impact Mobility and Are Common in Dogs with OA Pain *262*
18.2.4 Polypharmacy Is Often Employed in Dogs with OA Pain *263*
18.3 How the Environment Impacts OA and Pain *263*
18.3.1 Dogs Can Slip and Fall Too *263*
18.3.2 Changes in the Environment Can Contribute to Acute OA Flares *265*
18.4 The Environment and Patient Welfare: “Freedom from” Often Forgets “Freedom to” *265*
18.4.1 Sleep Needs *266*
18.4.2 Mental Engagement Needs *266*
18.5 Environmental Modifications: The Underappreciated Game Changer *267*
18.6 Making Recommendations Inspired by “Joint Protection” *268*
18.6.1 Veterinary Joint Protection in Action *268*
18.6.2 When Do You Introduce Veterinary “Joint Protection”? *269*
18.7 Engaging Your Team and the Caregiver to Implement Change *270*
18.7.1 Persuading the Caregiver *271*
18.7.2 Cognitive Biases and Beliefs *271*
18.7.3 Lack of Understanding *272*
18.7.4 Habits and Routines *272*
18.7.5 Emotional Factors *272*
18.8 What Do Environmental Modifications Look Like? *273*
18.8.1 Practical Solutions *273*
18.8.2 Environmental Modifications for Dogs with Mobility Issues (E.g. OA) *274*
References *277*

Part 5 Beyond the Basics: Adjunctive Therapies and Advanced Interventions *281*

19 Surgical Management of Joint Diseases and Osteoarthritis *283*
Christina DeArmond, Miranda de la Vega, and Laurent Guiot
19.1 Introduction *283*
19.2 Thoracic Limb Conditions and Associated Surgical Techniques *283*
19.2.1 Shoulder *283*
Osteochondritis Dissecans (OCD) *284*
Biceps Tendinopathy *284*
Supraspinatus Tendinopathy *286*
Shoulder Instability and Luxation *286*
End-stage Shoulder Disease *287*
19.2.2 Elbow *288*
Fragmented Medial Coronoid Process (FMCP) *288*
Ununited Anconeal Process (UAP) *290*
Osteochondritis Dissecans (OCD) *290*
Elbow Incongruity *291*
Elbow Luxation *291*
End-stage Elbow Arthritis *292*
19.2.3 Carpus *293*
Carpal Fractures *293*
Carpal Hyperextension *293*
End-stage Carpal Arthritis *295*
19.2.4 Digits *295*
19.3 Pelvic Limb Conditions and Associated Surgical Techniques *295*
19.3.1 Hip *295*
Hip Dysplasia *295*
Legg–Calvé–Perthes Disease *299*
19.3.2 Stifle *301*
Cranial Cruciate Ligament Disease *301*
Patellar Luxation *304*
Osteochondritis Dissecans (OCD) *308*
End-stage Stifle Management *309*
19.3.3 Tarsus *311*
OC/OCD *311*
End-stage Tarsus *311*
Total Ankle Replacement *312*
Pantarsal Arthrodesis *312*
Partial Tarsal Arthrodesis *312*
References *314*

20 Canine Rehabilitation: What It Is and What Techniques Can Help Dogs with OA *318*
Janet Van Dyke, Lindsey Fry, Jesscia Rychel, and Teri Lyn Willard
20.1 What Is Canine Rehabilitation? *318*
20.2 Applying Physical Therapy Principles to Assessing Canine Patients *319*
20.2.1 The PT/Rehabilitation Evaluation: Osteokinematics and Arthrokinematics *319*
20.3 Introduction to Therapeutic Techniques Used in Canine Rehabilitation *320*
20.3.1 Rehabilitation Equipment *321*
20.4 Manual Therapy for Canine OA *322*
20.5 Therapeutic Modalities for Canine OA *323*

20.5.1 Thermal Energy *323*
Cryotherapy (Ice) *323*
Thermotherapy (Heat Packs) *324*
20.5.2 Electromagnetic Energy *324*
Photobiomodulation (PBM) *324*
Pulsed Electromagnetic Field (PEMF) *326*
20.5.3 Acoustic Energy *326*
Therapeutic Ultrasound *327*
Extracorporeal Shock Wave Therapy (ESWT) *327*
Electrical Energy *329*
20.6 Integrating Rehabilitation into Practice *329*
References *330*

21 Joint Support Supplements: Do They Have a Place in Canine OA Management? *333*
Leilani X. Alvarez
21.1 Introduction *333*
21.2 Pharmaceuticals vs. Nutraceuticals *333*
21.3 Safety of Supplements *334*
21.4 What to Look for in a Quality Supplement *335*
21.5 Current Evidence *335*
21.5.1 Glucosamine and Chondroitin *335*
21.5.2 Omega-3 Fatty Acids *336*
21.5.3 Green-lipped Mussel (*Perna canaliculus*) *338*
21.5.4 Undenatured Type II Collagen (UC-II®) *338*
21.5.5 Eggshell Membrane (ESM) *338*
21.5.6 Hyaluronic Acid (HA) *338*
21.5.7 Herbals *338*
Cannabinoids *338*
Curcumin *339*
Boswellia serrata *339*
21.5.8 Antioxidants *339*
Astaxanthin (ASX) *340*
21.5.9 Injectable Joint Support Products *340*
Polysulfated Glycosaminoglycan (PSGAG, Adequan®) *340*
Pentosan Polysulfate Sodium (PPS, Cartrophen Vet) *341*
21.6 Implementation in a Multimodal OA Plan *341*
References *341*

22 Intra-Articular Therapies *345*
Jessica Rychel, Lindsey Fry, and Arielle Pechette Markley
22.1 Introduction to Intra-Articular Therapies for OA *345*
22.2 Considerations for Joint Injections *345*
22.3 What to Inject Into the Joint *346*
22.3.1 Hyaluronic Acid (HA) *346*
22.3.2 Corticosteroids *347*
22.3.3 Platelet-Rich Plasma (PRP) *347*
22.3.4 Autologous Protein Solution (APS)/Autologous Conditioned Serum (ACS) *348*
22.3.5 Autogenous Mesenchymal Stem Cells *349*
22.3.6 Polyacrylamide Hydrogel *350*
22.3.7 Collagen–Elastin Hydrogel Particles *351*
22.3.8 Radiosynoviorthesis with Sn-117m (Synovetin OA™) *352*
References *354*

23 Acupuncture for OA Management: Scientific Rationale and Practical Recommendations *359*
Lindsey Fry and Arielle Pechette Markley
23.1 What Is Acupuncture and How Does It Work? *359*
23.2 Acupuncture in OA Management *359*
23.2.1 Acupuncture for Local Disease Management – Modification of the Inflammatory Joint *360*
23.2.2 Acupuncture for Pain Management in OA *360*
23.2.3 Acupuncture for Myofascial Dysfunction *362*
23.3 The Acupuncture Visit: Practical Tips *362*
References *365*

Part 6 Graceful Goodbyes: Supporting Dogs and Caregivers Through the Final Stages of OA *369*

24 When It's Not Quite Time: Palliative and Hospice Care *371*
Sheilah A. Robertson and Bonnie D. Wright
24.1 Introduction *371*
24.2 Palliative and Hospice Care *372*
24.2.1 Integrative Medical Approach *372*
24.3 Pharmacologic Interventions *373*
24.3.1 *N*-Methyl-D-Aspartate (NMDA) Receptor Antagonists *373*
24.3.2 Acetaminophen (Paracetamol) *373*
24.3.3 Anxiolytics *374*
24.3.4 Corticosteroids *375*
24.4 Non-Pharmacologic Modalities *375*
24.4.1 Heat *375*
24.4.2 Electromagnetic Fields *376*
24.4.3 Light Therapy *376*
24.4.4 Therapeutic Diets and Supplements *376*
24.4.5 Mobility Assistance Devices and Environmental Modifications *376*
24.5 Treatment of Myofascial Pain Syndrome *377*
24.6 Euthanasia *377*
References *378*

25 When Pain Wins: End-of-Life Decision-Making *381*
Mary Gardner
25.1 Why This Topic Is Important *381*
25.2 The Many Facets of Diminished Mobility *381*
25.3 The Quality-of-Life Elements *382*
25.3.1 Element 1: The Disease and How It Will Progress *382*
25.3.2 Element 2: Assessing the Patient's Personality and Emotional Well-being *382*
25.3.3 Element 3: Family Beliefs and Differences *383*
25.3.4 Element 4: The Four Critical Budgets of Pet Care *383*
25.4 Aligning a Family's Capacity With Their Pet's Disease Progression *384*
25.4.1 The Pattern of Waiting Too Long *384*
25.4.2 Considering a Natural Death *385*
25.4.3 Does Science Provide a Clear Answer of "When Is Time"? *385*
25.5 The Role of Quality-of-Life Assessment Tools *385*
25.5.1 The Top Five Method *386*
25.5.2 The Five Freedoms as a Guide for End-of-Life Care *386*

25.5.3 Defining Good Days vs. Bad Days *386*
25.5.4 Tracking Good Days and Bad Days *387*
25.6 An SOS from Denial Island *387*
25.7 No Simple Answer – Only Thoughtful Guidance *388*
25.7.1 Supporting Families Through the Final Journey *388*
Reference *389*

Index *390*